FOXO4-DRI for Longevity
Senolytic D-retro-inverso peptide that disrupts FOXO4-p53 to selectively kill senescent cells.
Why FOXO4-DRI for longevity?
FOXO4-DRI is a 30-aa D-retro-inverso peptide developed by Peter de Keizer's lab (Cell, 2017). It disrupts the FOXO4-p53 interaction in senescent cells, restoring p53 nuclear exclusion and triggering apoptosis. Mouse data showed improved fur density, fitness, and renal function. No published human trials; only research-grade material is available.
Longevity context: Targeting senescent cells, mitochondrial function, telomere maintenance, and cellular resilience. FOXO4-DRI fits this goal because its category (Longevity) and benefit profile align with the underlying mechanism.
Benefits relevant to longevity
- Selective senolysis
- Restored fitness in aged mice
- Hair regrowth (mouse studies)
Reference dosing by bodyweight
Anchored to the most-cited research dose (250 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 156–211 mcg |
| 60–75 kg / 132–165 lb | 191–259 mcg |
| 75–90 kg / 165–198 lb | 234–316 mcg |
| 90–105 kg / 198–231 lb | 276–374 mcg |
| >105 kg / >231 lb | 319–431 mcg |
Side effects to weigh against longevity benefit
- Unstudied in humans
- Theoretical immune/cytokine reactions
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.